FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169331014> ?p ?o ?g. }

• W2169331014 endingPage "3837" @default.
• W2169331014 startingPage "3831" @default.
• W2169331014 abstract "Purpose This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with non–small-cell lung cancer (NSCLC). Patients and Methods This double-blind phase III trial randomly assigned 731 patients with NSCLC who had progressed after prior chemotherapy to erlotinib 150 mg daily or placebo, with survival as the primary study outcome. QOL was assessed by European Organisation for Research and Treatment of Cancer QLQ-C30 and the lung cancer module QLQ-LC13. The primary end points for QOL analysis were time to deterioration of three common lung cancer symptoms: cough, dyspnea, and pain. Results Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm. Compliance with QOL was 87% at baseline and more than 70% during treatment. Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03]). QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively. This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001). Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01). Conclusion Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL." @default.
• W2169331014 created "2016-06-24" @default.
• W2169331014 creator A5004386291 @default.
• W2169331014 creator A5005937823 @default.
• W2169331014 creator A5012396032 @default.
• W2169331014 creator A5017180340 @default.
• W2169331014 creator A5018164318 @default.
• W2169331014 creator A5026119562 @default.
• W2169331014 creator A5028859301 @default.
• W2169331014 creator A5035183458 @default.
• W2169331014 creator A5040285878 @default.
• W2169331014 creator A5044291041 @default.
• W2169331014 creator A5046728958 @default.
• W2169331014 creator A5047980046 @default.
• W2169331014 creator A5053429111 @default.
• W2169331014 creator A5059878377 @default.
• W2169331014 creator A5063121757 @default.
• W2169331014 creator A5075347427 @default.
• W2169331014 creator A5081974555 @default.
• W2169331014 creator A5088824925 @default.
• W2169331014 date "2006-08-20" @default.
• W2169331014 modified "2023-10-18" @default.
• W2169331014 title "Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
• W2169331014 cites W1483985834 @default.
• W2169331014 cites W1548492938 @default.
• W2169331014 cites W169321572 @default.
• W2169331014 cites W1839238860 @default.
• W2169331014 cites W1947168884 @default.
• W2169331014 cites W1999784741 @default.
• W2169331014 cites W2006994284 @default.
• W2169331014 cites W2031059868 @default.
• W2169331014 cites W2041130945 @default.
• W2169331014 cites W2049484790 @default.
• W2169331014 cites W2058680827 @default.
• W2169331014 cites W2105024669 @default.
• W2169331014 cites W2106155834 @default.
• W2169331014 cites W2109567704 @default.
• W2169331014 cites W2115012618 @default.
• W2169331014 cites W2120718661 @default.
• W2169331014 cites W2125541970 @default.
• W2169331014 cites W2127342594 @default.
• W2169331014 cites W2130652363 @default.
• W2169331014 cites W2134667653 @default.
• W2169331014 cites W2138297714 @default.
• W2169331014 cites W2146404049 @default.
• W2169331014 cites W2154948351 @default.
• W2169331014 cites W2167571044 @default.
• W2169331014 cites W2290328391 @default.
• W2169331014 cites W4247516533 @default.
• W2169331014 cites W4247732120 @default.
• W2169331014 cites W81256119 @default.
• W2169331014 doi "https://doi.org/10.1200/jco.2006.05.8073" @default.
• W2169331014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16921034" @default.
• W2169331014 hasPublicationYear "2006" @default.
• W2169331014 type Work @default.
• W2169331014 sameAs 2169331014 @default.
• W2169331014 citedByCount "277" @default.
• W2169331014 countsByYear W21693310142012 @default.
• W2169331014 countsByYear W21693310142013 @default.
• W2169331014 countsByYear W21693310142014 @default.
• W2169331014 countsByYear W21693310142015 @default.
• W2169331014 countsByYear W21693310142016 @default.
• W2169331014 countsByYear W21693310142017 @default.
• W2169331014 countsByYear W21693310142018 @default.
• W2169331014 countsByYear W21693310142019 @default.
• W2169331014 countsByYear W21693310142020 @default.
• W2169331014 countsByYear W21693310142021 @default.
• W2169331014 countsByYear W21693310142022 @default.
• W2169331014 countsByYear W21693310142023 @default.
• W2169331014 crossrefType "journal-article" @default.
• W2169331014 hasAuthorship W2169331014A5004386291 @default.
• W2169331014 hasAuthorship W2169331014A5005937823 @default.
• W2169331014 hasAuthorship W2169331014A5012396032 @default.
• W2169331014 hasAuthorship W2169331014A5017180340 @default.
• W2169331014 hasAuthorship W2169331014A5018164318 @default.
• W2169331014 hasAuthorship W2169331014A5026119562 @default.
• W2169331014 hasAuthorship W2169331014A5028859301 @default.
• W2169331014 hasAuthorship W2169331014A5035183458 @default.
• W2169331014 hasAuthorship W2169331014A5040285878 @default.
• W2169331014 hasAuthorship W2169331014A5044291041 @default.
• W2169331014 hasAuthorship W2169331014A5046728958 @default.
• W2169331014 hasAuthorship W2169331014A5047980046 @default.
• W2169331014 hasAuthorship W2169331014A5053429111 @default.
• W2169331014 hasAuthorship W2169331014A5059878377 @default.
• W2169331014 hasAuthorship W2169331014A5063121757 @default.
• W2169331014 hasAuthorship W2169331014A5075347427 @default.
• W2169331014 hasAuthorship W2169331014A5081974555 @default.
• W2169331014 hasAuthorship W2169331014A5088824925 @default.
• W2169331014 hasBestOaLocation W21693310141 @default.
• W2169331014 hasConcept C121608353 @default.
• W2169331014 hasConcept C126322002 @default.
• W2169331014 hasConcept C141071460 @default.
• W2169331014 hasConcept C142724271 @default.
• W2169331014 hasConcept C143998085 @default.
• W2169331014 hasConcept C159110408 @default.
• W2169331014 hasConcept C204787440 @default.
• W2169331014 hasConcept C207103383 @default.
• W2169331014 hasConcept C27081682 @default.

• next